The relationship between Alzheimer's disease and diabetes: Type 3 diabetes?
- PMID: 20030463
The relationship between Alzheimer's disease and diabetes: Type 3 diabetes?
Abstract
In recent years, Alzheimer's disease (AD) has been considered to be, in part, a neuroendocrine disorder, even referred to by some as type 3 diabetes. Insulin functions by controlling neurotransmitter release processes at the synapses and activating signaling pathways associated with learning and long-term memory. Novel research demonstrates that impaired insulin signaling may be implicated in AD. Post-mortem brain studies show that insulin expression is inversely proportional to the Braak stage of AD progression. It was also demonstrated that neurotoxins, coined amyloid beta-derived diffusible ligands (ADDLs), disrupt signal transduction at synapses, making the cell insulin resistant. ADDLs reduce plasticity of the synapse, potentiate synapse loss, contribute to oxidative damage, and cause AD-type tau hyperphosphorylation. Diabetes and AD have signs of increased oxidative stress in common, including advanced glycation end products (AGEs), when compared to normal subjects. Diabetic patients appear to have an increased risk for AD because AGEs accumulate in neurofibrillary tangles and amyloid plaques in AD brains. This research should encourage a more proactive approach to early diagnosis of diabetes and nutritional counseling for AD patients.
Similar articles
-
Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease.Med Hypotheses. 2005;64(6):1205-7. doi: 10.1016/j.mehy.2005.01.016. Med Hypotheses. 2005. PMID: 15823718
-
Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus.Neurobiol Dis. 2010 Jan;37(1):67-76. doi: 10.1016/j.nbd.2009.09.008. Epub 2009 Sep 22. Neurobiol Dis. 2010. PMID: 19778613
-
N epsilon-carboxymethyllysine in brain aging, diabetes mellitus, and Alzheimer's disease.Free Radic Biol Med. 2004 May 15;36(10):1241-7. doi: 10.1016/j.freeradbiomed.2004.02.006. Free Radic Biol Med. 2004. PMID: 15110389
-
Molecular mechanisms linking diabetes mellitus and Alzheimer disease: beta-amyloid peptide, insulin signaling, and neuronal function.Mol Biosyst. 2011 Jun;7(6):1822-7. doi: 10.1039/c0mb00302f. Epub 2011 Mar 24. Mol Biosyst. 2011. PMID: 21431241 Review.
-
The model Caenorhabditis elegans in diabetes mellitus and Alzheimer's disease.J Alzheimers Dis. 2009;16(4):897-908. doi: 10.3233/JAD-2009-0977. J Alzheimers Dis. 2009. PMID: 19387121 Review.
Cited by
-
The role of glucose transporters in brain disease: diabetes and Alzheimer’s Disease.Int J Mol Sci. 2012 Oct 3;13(10):12629-55. doi: 10.3390/ijms131012629. Int J Mol Sci. 2012. PMID: 23202918 Free PMC article. Review.
-
Pathology, Risk Factors, and Oxidative Damage Related to Type 2 Diabetes-Mediated Alzheimer's Disease and the Rescuing Effects of the Potent Antioxidant Anthocyanin.Oxid Med Cell Longev. 2021 Feb 27;2021:4051207. doi: 10.1155/2021/4051207. eCollection 2021. Oxid Med Cell Longev. 2021. PMID: 33728019 Free PMC article. Review.
-
Reconsidering repurposing: long-term metformin treatment impairs cognition in Alzheimer's model mice.Transl Psychiatry. 2024 Jan 18;14(1):34. doi: 10.1038/s41398-024-02755-9. Transl Psychiatry. 2024. PMID: 38238285 Free PMC article.
-
Methylglyoxal alters glucose metabolism and increases AGEs content in C6 glioma cells.Metab Brain Dis. 2012 Dec;27(4):531-9. doi: 10.1007/s11011-012-9329-3. Epub 2012 Jul 18. Metab Brain Dis. 2012. PMID: 22802013
-
Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease.Acta Pharm Sin B. 2022 Feb;12(2):511-531. doi: 10.1016/j.apsb.2021.06.014. Epub 2021 Jun 30. Acta Pharm Sin B. 2022. PMID: 35256932 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical